AbCellera Biologics
ABCL
ABCL
161 hedge funds and large institutions have $1.22B invested in AbCellera Biologics in 2022 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 53 increasing their positions, 28 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
10% more capital invested
Capital invested by funds: $1.1B → $1.22B (+$112M)
1.55% more ownership
Funds ownership: 39.97% → 41.52% (+1.6%)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Holders
161
Holding in Top 10
7
Calls
$35.3M
Puts
$18.9M
Top Buyers
| 1 | +$99.9M | |
| 2 | +$31.2M | |
| 3 | +$24.6M | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.4M |
| 5 |
Millennium Management
New York
|
+$15.6M |
Top Sellers
| 1 | -$77.4M | |
| 2 | -$55.7M | |
| 3 | -$25.6M | |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$10.5M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$5.44M |